ORIGINAL RESEARCH article
Front. Cell. Infect. Microbiol.
Sec. Intestinal Microbiome
Volume 15 - 2025 | doi: 10.3389/fcimb.2025.1602792
This article is part of the Research TopicImpact of Gut Probiotic Metabolites on Human Metabolic DiseasesView all 8 articles
Saccharomyces boulardii (CNCM I-745) improves intestinal damage in sepsis by remodeling intestinal flora structure
Provisionally accepted- 1The Sixth Affiliated Hospital of Harbin Medical University, Harbin, China
- 2First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang Province, China
- 3Departments of Critical Care Medicine, First Affiliated Hospital of Harbin Medical University, Harbin, Jilin Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Sepsis is one of the leading causes of mortality among intensive care unit (ICU) patients. The intestinal tract is the primary organ affected by sepsis, resulting in dysbiosis of the gut microbiota and negatively impacting long-term prognosis. This study investigated the protective effects of Saccharomyces boulardii (S. boulardii) on intestinal damage during sepsis.Methods: Distilled water was administered orally by intragastric for 4 weeks in control group and sepsis group. S. boulardii (CNCM I-745) suspension (10 8 CFU/ml) was administered orally by intragastric for 4 weeks in probiotic group and treatment group. Rats in control group and probiotic group received the intraperitoneal injection of normal saline (5ml/kg).Rats in sepsis group and treatment group received the intraperitoneal injection of LPS solution (1mg/ml). Eight hours after the intraperitoneal injection, samples of serum, colonic tissue, and colonic contents were collected and stored at -80℃. Four weeks later, the samples of colonic contents were taken to observe the alterations in the intestinal microbiota.Results: Sepsis led to an increase in the expression of IL-6, TNF-α,and a decrease in the expression of occludin. After treatment with S. boulardii (CNCM I-745), the inflammatory damage with sepsis was reduced, and the expression level of occludin was significantly increased. High-throughput sequencing analysis revealed that sepsis injury led to a decline in both the diversity and abundance of the gut microbiota. Simultaneously, the colonization of beneficial bacteria within the intestine diminished, whereas the colonization of harmful bacteria surged. However, upon administration of S. boulardii (CNCM I-745), an increase in the diversity and abundance of the gut microbiota was evident. Moreover, the composition of the gut microbiota underwent a discernible alteration.: Sepsis induces impairment of intestinal barrier function and exacerbates inflammatory responses. The use of S. boulardii (CNCM I-745) can modulate the composition of the intestinal flora by enhancing the colonization of beneficial bacteria while reducing the presence of harmful bacteria. It helps maintain intestinal mucosal barrier function, mitigates intestinal damage associated with sepsis, and potentially influences the long-term growth and development of pediatric sepsis patients.
Keywords: Saccharomyces boulardii, Sepsis, Gut Microbiota, Gut barrier dysfunction, 16S rRNA gene sequencing
Received: 30 Mar 2025; Accepted: 09 Jul 2025.
Copyright: © 2025 Gao, Liu, Li, Yilu, Yujia, Zhao, Xu, Wang, Zhi, Zhang, Deng, Kang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yang Gao, The Sixth Affiliated Hospital of Harbin Medical University, Harbin, China
Kai Kang, Departments of Critical Care Medicine, First Affiliated Hospital of Harbin Medical University, Harbin, Jilin Province, China
Ying Chen, First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.